EZH2 and breast cancer: Typically, GSK343 and GSK926 are suggested to down-regulate histone H3K27me3 expression while suppressing EZH2 expression within BC (HCC1806 TNBC) and PCa (LNCaP) cells; nonetheless, GSK343 displays certain limitations because it is highly cleared (plasma volume where the drug is completely eliminated per unit of time) in a rat pharmacokinetic study.